India’s position as a pivotal player in the global biologics manufacturing landscape has gained significant attention, particularly during the BioAsia 2026 conference. Industry leaders highlighted the country’s ability to scale complex technologies, which encompass a wide range of advanced therapies including vaccines, RNA platforms, and cell and gene therapies.
Collaborative Innovation
The panel discussion, moderated by Gil Bashe of Finn Partners, emphasized that the future of biologics innovation hinges on collaboration rather than isolated efforts. Key executives and clinicians underscored the necessity of a robust manufacturing infrastructure and the capacity to deliver therapies on a large scale. The collaborative spirit among stakeholders is crucial for overcoming the challenges that accompany the development of next-generation therapies.
India’s Vaccine Manufacturing Prowess
Raches Ella, Chief Development Officer of Bharat Biotech, articulated India’s vital role in global vaccine production. He noted that one-third of children worldwide receive vaccines manufactured in India. This extensive manufacturing capability encompasses every stage, from research and development to commercial production. Ella expressed the ambition to reach approximately 125 million children annually, showcasing India’s potential in addressing global health needs.
A Risk-Taking Market
Jose Castillo, CEO of Quantoom Biosciences, described India as a pioneering market for biomanufacturing innovation. He reminisced about the deployment of some of the first commercial bioreactors utilizing his technology in India. This early adoption has positioned the country as a critical hub for advancing research and development in the biomanufacturing sector.
Building a Manufacturing Ecosystem
Darrin Morrissey, CEO of the National Institute for Bioprocessing Research and Training, highlighted the significance of a well-established manufacturing ecosystem. Drawing from Ireland’s experience, he pointed out that the country has invested over two decades in developing biologics manufacturing capabilities in collaboration with multinational firms. With annual biologic medicine production valued at €100 billion, Ireland exemplifies the success that can arise from strategic partnerships.
Industrializing Complex Therapies
Simpson V. Emmanuel, president of ImmunoACT, brought attention to India’s potential in industrializing intricate therapies such as CAR-T cell therapy. He characterized this advancement as a significant shift from traditional pharmaceutical manufacturing, reinforcing India’s capability to innovate in complex therapeutic areas.
Access to Transformative Therapies
The discussion also raised concerns about equitable access to innovative therapies. Sai Praveen Haranath, senior vice-president at Apollo Health Axis, pointed out that despite the emergence of transformative therapies, many individuals globally still lack access to essential medicines. This gap emphasizes the need for strategic initiatives that ensure widespread availability of life-saving treatments.
Exploring New Therapeutic Frontiers
Madhuri Vusirikala, vice-president of Clinical Development at Actinium Pharmaceuticals, highlighted the underdevelopment of radioligand therapies in India. She noted the significant unmet need for these therapies and the ample opportunity for conducting clinical trials to enhance patient access to cutting-edge treatments. This aspect underscores the potential for growth within the Indian biopharmaceutical landscape.
Future Directions
The insights shared during BioAsia 2026 spotlight India’s evolving capabilities in the biologics sector. As the country continues to strengthen its manufacturing infrastructure and foster international collaborations, it is poised to play an even more significant role in global health.
In conclusion, India’s emerging prominence in next-generation biologics reflects a powerful convergence of innovation, collaboration, and manufacturing expertise. The discussions at BioAsia 2026 not only celebrate past achievements but also pave the way for future advancements that could transform global healthcare.
- India produces vaccines for one in three children worldwide.
- The country is recognized for its early adoption of biomanufacturing innovation.
- Strategic partnerships are essential for developing a robust manufacturing ecosystem.
- There is a pressing need for equitable access to transformative therapies.
- Opportunities exist for expanding clinical trials in underdeveloped therapeutic areas.
Read more → www.thehindu.com